Global Urea Cycle Disorders Treatment Market Anticipated to Undergo Strong Growth Through 2030

The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided.

What Is the Projected Growth Rate of the Urea Cycle Disorders Treatment Market Through 2030?
The urea cycle disorders treatment market size has grown steadily in recent years. It will grow from $1.37 billion in 2025 to $1.43 billion in 2026 at a compound annual growth rate (CAGR) of 3.8%. The growth in the historic period can be attributed to lack of awareness about ucd, limited treatment options, low patient diagnosis rates, high treatment costs, dependence on hospital-based care.

The urea cycle disorders treatment market size is expected to see steady growth in the next few years. It will grow to $1.71 billion in 2030 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to growth in gene therapy research, rising adoption of precision medicine, technological advancements in ammonia monitoring, increasing pediatric patient focus, expansion of home healthcare services. Major trends in the forecast period include personalized ucd therapy development, improved ammonia scavenger formulations, enzyme replacement therapy advancements, pediatric-focused treatment innovations, home-based and remote monitoring solutions.

Claim your free report sample now:
https://www.thebusinessresearchcompany.com/report/urea-cycle-disorders-treatment-global-market-report

Which Drivers Are Positively Impacting the Urea Cycle Disorders Treatment Market?
The rising number of chronic kidney disorder cases is expected to propel the growth of the urea cycle disorders treatment market going forward. Chronic kidney disease (CKD) is a long-term condition characterized by the gradual loss of kidney function over time. Chronic kidney disorder utilizes urea cycle disorder treatment to manage metabolic waste, particularly elevated levels of urea, as impaired kidney function hinders proper waste excretion. For instance, in November 2023, according to Kidney Care UK, a UK-based kidney patient support charity, approximately 7.2 million individuals are estimated to have chronic kidney disease (CKD) stages 1–5, with around 3.5 million people in the UK experiencing the later stages of CKD (stages 3-5), during which symptoms are expected to become progressively challenging to control. Therefore, the rising number of chronic kidney disorder cases is driving the growth of the urea cycle disorders treatment market.

How Is the Urea Cycle Disorders Treatment Market Arranged by Segment Classification?
The urea cycle disorders treatment market covered in this report is segmented –

1) By Treatment: Amino Acid Supplements, Sodium Phenylbutyrate, Glycerol Phenylbutyrate, Sodium Benzoate, Other Treatments
2) By Enzyme Deficiency: Ornithine Transcarbamylase (OTC), Argininosuccinate Synthetase (AS), Arginase (AG), Argininosuccinate Lyase (AL), Carbamoyl Phosphate Synthase (CPS1)
3) By Route of Administration: Oral, Injectables
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Amino Acid Supplements: Arginine Supplements, Citrulline Supplements, Other Essential Amino Acids
2) By Sodium Phenylbutyrate: Powder Form, Tablet Form
3) By Glycerol Phenylbutyrate: Oral Solutions, Other Forms
4) By Sodium Benzoate: Intravenous Solutions, Oral Formulations
5) By Other Treatments: Liver Transplantation, Dietary Modifications, Enzyme Replacement Therapy, Other Supportive Therapies

What Are the Most Prominent Trends Impacting the Urea Cycle Disorders Treatment Market?
Major companies operating in the urea cycle disorder treatment industry are adopting a strategic partnership approach to innovative therapies and improving disease management. Strategic partnerships refer to a process in which companies leverage each other's strengths and resources to achieve mutual benefits and success. For instance, in June 2024, Orsini Specialty Pharmacy, a US-based personalized care and medications provider, and Zevra Therapeutics Inc., a US-based rare disease therapeutics company, announced that Orsini is the pharmacy partner for OLPRUVA (sodium phenylbutyrate) oral suspension. OLPRUVA is a prescription medication used in combination with certain therapies, including dietary changes, for the long-term management of urea cycle disorders (UCDs) in specific adult and pediatric patients with deficiencies in carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS).

Who Are the Emerging Players in the Urea Cycle Disorders Treatment Market?
Major companies operating in the urea cycle disorders treatment market are Bausch Health Companies Inc., Recordati Rare Diseases, Eurocept Pharmaceuticals Holding, Acer Therapeutics, Ultragenyx Pharmaceutical, Aeglea BioTherapeutics, Arcturus Therapeutics Inc., Orpharma Pty Ltd., Horizon Therapeutics Plc, Synlogic, Amicus Therapeutics, Sobi, PTC Therapeutics, Chiesi Farmaceutici S.p.A., Astellas Pharma Inc., Protalix BioTherapeutics, Erytech Pharma, Relief Therapeutics Holding AG, Selecta Biosciences Inc., Argenx SE, Dynacure SA, Inventiva SA

Get the full urea cycle disorders treatment market report here:
https://www.thebusinessresearchcompany.com/report/urea-cycle-disorders-treatment-global-market-report

Which regions are expected to dominate the Urea Cycle Disorders Treatment Market during the forecast period?
North America was the largest region in the urea cycle disorders treatment market in 2025. The regions covered in the urea cycle disorders treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: Global Market Research Reports & Consulting | The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: The Business Research Company | LinkedIn